Adam S Sperling
Overview
Explore the profile of Adam S Sperling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
2416
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mouhieddine T, Nzerem C, Redd R, Dunford A, Leventhal M, Sklavenitis-Pistofidis R, et al.
Cancer Res Commun
. 2023 Nov;
3(12):2560-2571.
PMID: 38019104
Significance: Using our algorithm to differentiate tumor and germline mutations from CH mutations, we detected CH in approximately 10% of patients with newly diagnosed myeloma, including both transplant eligible and...
12.
Midha S, Hartley-Brown M, Mo C, Hossain S, Nadeem O, ODonnell E, et al.
Expert Opin Drug Saf
. 2023 Oct;
22(11):1049-1071.
PMID: 37906232
Introduction: Multiple new drugs have been approved over the past 5 years for the treatment of relapsed/refractory multiple myeloma (RRMM), and these are being increasingly widely used. Clinicians need to...
13.
Chen C, Zhang L, Dutta R, Niroula A, Miller P, Gibson C, et al.
Cell Stem Cell
. 2023 Oct;
30(11):1503-1519.e8.
PMID: 37863054
Somatic mutations accumulate in all cells with age and can confer a selective advantage, leading to clonal expansion over time. In hematopoietic cells, mutations in a subset of genes regulating...
14.
Mo C, Yee A, Midha S, Hartley-Brown M, Nadeem O, ODonnell E, et al.
EJHaem
. 2023 Aug;
4(3):792-810.
PMID: 37601856
Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that inhibits exportin-1 (XPO1), a novel therapeutic target that is overexpressed in multiple myeloma (MM) and is responsible for...
15.
Miller P, Sperling A, Mayerhofer C, McConkey M, Ellegast J, Da Silva C, et al.
Blood
. 2023 Aug;
142(24):2079-2091.
PMID: 37595362
PPM1D encodes a phosphatase that is recurrently activated across cancer, most notably in therapy-related myeloid neoplasms. However, the function of PPM1D in hematopoiesis and its contribution to tumor cell growth...
16.
Shah P, Sperling A
Hematol Oncol Clin North Am
. 2023 Aug;
37(6):1089-1105.
PMID: 37563077
Multiple myeloma is the second most common hematological malignancy with an approximate incidence of up to 8.5 cases per 100,000 persons per year. Over the last decade, therapy for multiple...
17.
Little J, Tandon M, Hong J, Nadeem O, Sperling A, Raje N, et al.
Blood Adv
. 2023 Jul;
7(18):5485-5495.
PMID: 37486599
Infections are an important complication after B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy and risks may differ between the early and late periods. We evaluated infections in...
18.
Tsai J, Aguirre J, Li Y, Brown J, Focht V, Kater L, et al.
Mol Cell
. 2023 Jul;
83(15):2753-2767.e10.
PMID: 37478846
Nuclear hormone receptors (NRs) are ligand-binding transcription factors that are widely targeted therapeutically. Agonist binding triggers NR activation and subsequent degradation by unknown ligand-dependent ubiquitin ligase machinery. NR degradation is...
19.
Liu X, Moscvin M, Oh S, Chen T, Choi W, Evans B, et al.
Clin Exp Med
. 2023 Jul;
23(7):3821-3832.
PMID: 37421589
Multiple myeloma (MM) is a cancer of terminally differentiated plasma cells. MM remains incurable, but overall survival of patients has progressively increased over the past two decades largely due to...
20.
Gibson C, Fell G, Sella T, Sperling A, Snow C, Rosenberg S, et al.
Clin Cancer Res
. 2023 Apr;
29(13):2551-2558.
PMID: 37115512
Purpose: Young women treated for breast cancer with cytotoxic therapies are at risk for clonal hematopoiesis of indeterminate potential (CHIP), a condition in which blood cells carrying a somatic mutation...